Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Show more

Location: 131 Dartmouth Street, Boston, MA, 02116, United States | Website: https://www.adicetbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

92.31M

52 Wk Range

$0.45 - $1.19

Previous Close

$0.58

Open

$0.58

Volume

981,864

Day Range

$0.58 - $0.63

Enterprise Value

4.437M

Cash

103.1M

Avg Qtr Burn

-24.61M

Insider Ownership

1.46%

Institutional Own.

36.35%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADI-001 Details Rheumatoid Arthritis (RA)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Idiopathic inflammatory myopathy / myositis, Stiff Person Syndrome	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADI-270 Details Cancer, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.